Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
palbociclib + 5-fluorouracil + oxaliplatin + leucovorin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy regimen consists of the CDK4/6 inhibitor palbociclib (PD-0332991) and the chemotherapy agents 5-fluorouracil (5-FU), oxaliplatin, and leucovorin. The regimen was investigated in a Phase I clinical trial (NCT01522989) led by Georgetown University for the treatment of advanced solid tumor malignancies. Palbociclib is a targeted therapy that inhibits cyclin-dependent kinases 4 and 6, leading to G1 cell cycle arrest and preventing cancer cell proliferation. 5-fluorouracil is an antimetabolite that inhibits thymidylate synthase, while oxaliplatin is a platinum-based agent that causes DNA cross-linking and damage. Leucovorin is included to potentiate the effects of 5-fluorouracil. The combination aims to exploit potential synergies between cell cycle synchronization and cytotoxic DNA damage to overcome treatment resistance in advanced cancers.
- Brand names
- IbranceEloxatinAdrucil
- Other names
- PD-0332991 + 5-FU + OxaliplatinPalbociclib + 5-FU + OxaliplatinPalbociclib + 5-Fluorouracil + Oxaliplatin + Leucovorin
02
Targets
TS (Thymidylate synthase)CDK6 (Cyclin-dependent kinase 6)DNACDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on palbociclib + 5-fluorouracil + oxaliplatin + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on palbociclib + 5-fluorouracil + oxaliplatin + leucovorin.